Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000451 · ClinicalTrials.gov registry record · Phase 2
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
A Phase 2 study of Alcoholism and Alcohol Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
- 1
- Study location
NCT00000451: Completed Phase 2 study of Alcoholism and Alcohol Dependence, sponsored by Yale University.
NCT00000451 is a Phase 2 study of Alcoholism and Alcohol Dependence that has completed, run by Yale University. The registered enrollment target is 198 participants, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000451, a Phase 2 study of Alcoholism and Alcohol Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
Conditions Studied
Interventions
- DRUG sertraline
- DRUG naltrexone
Study Locations (1)
Connecticut
- - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00000451 record still lists
NCT00000451 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which sertraline is the first listed.
NCT00000451 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00000451 about?
NCT00000451 is a clinical study titled "Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)". This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individua...
What is the current status of trial NCT00000451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2003-01. Estimated completion is 2005-11.
What conditions does trial NCT00000451 study?
This clinical trial studies the following conditions: Alcoholism, Alcohol Dependence.
What interventions are being tested in trial NCT00000451?
The interventions under investigation include: sertraline (DRUG), naltrexone (DRUG).
Who is sponsoring clinical trial NCT00000451?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000451 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000451's enrollment target sits among peer trials
198 18th of 65 higher than 48 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia